Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Marika Ciprotti"'
Autor:
Fook-Thean Lee, Peter Ansell, Hao Xiong, Benjamin Solomon, Marika Ciprotti, Andrew M. Scott, JuDee Fischer, Edward B. Reilly, Rod A. Humerickhouse, Wijith Munasinghe, Matthew Burge, Yumin Zhang, Kyle D. Holen, Hui K Gan, Sze Ting Lee, Gerard B. Fox
Publikováno v:
Journal of Nuclear Medicine. 62:787-794
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of 111In-radiolabeled ABT-806 (ABT-806i) and effects of repeated doses of ABT-806 on recepto
Autor:
Peter J. Hudson, Pece Kocovski, Ian D. Davis, John Pedersen, Andrew M. Scott, Sze Ting Lee, Scott Williams, Fook-Thean Lee, Graeme O'Keefe, Tim Akhurst, Andrew Weickhardt, Hui K Gan, Michael Paul Wheatcroft, Maggie Oh, Marika Ciprotti, Fiona Scott, Sylvia J. Gong, Linda Mileshkin, Kunthi Pathmaraj, Nancy Guo, Declan G. Murphy, Rodney J. Hicks
Publikováno v:
Theranostics
Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor. We report the preclinical and clini
Autor:
Howard M. Sandler, Stephen J. Freedland, Neal D. Shore, Matthew Raymond Smith, Rosamerlinda S. Rosales, Sabine D. Brookman-May, David P. Dearnaley, Adam P. Dicker, Michael R. McKenzie, Alberto Bossi, Anders Widmark, Thomas Wiegel, Jason L. Martin, Branko Miladinovic, Jennifer Anne Whalen, Marika Ciprotti, Sharon McCarthy, Suneel Mundle, Bertrand F. Tombal, Felix Y Feng
Publikováno v:
Journal of Clinical Oncology. 40:5084-5084
5084 Background: Current management of HRLPC includes long-term ADT with primary RT. Despite definitive primary treatment, these pts have a high risk of metastasis and death. The phase 3 ATLAS study (NCT02531516) is investigating whether treatment in
Autor:
Hui K, Gan, Matthew, Burge, Benjamin, Solomon, Sze Ting, Lee, Kyle D, Holen, Yumin, Zhang, Marika, Ciprotti, F T, Lee, Wijith, Munasinghe, JuDee, Fischer, Peter, Ansell, Gerard, Fox, Hao, Xiong, Edward B, Reilly, Rod, Humerickhouse, Andrew M, Scott
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 62(6)
ABT-806 is a tumor-specific antibody targeting the epidermal growth factor receptor (EGFR). This study assessed safety, biodistribution, and pharmacokinetics of
Autor:
Hakim Mahammedi, Matthew D. Galsky, Marika Ciprotti, Gwenaelle Gravis, Abdel Saci, Aude Flechon, Russell K. Pachynski, Yanhua Hu, Sumit K. Subudhi, Karim Fizazi, Akash Patnaik, Vivek Narayan, Padmanee Sharma, G. Celine Han, Burcin Simsek
Publikováno v:
Cancer cell. 38(4)
Summary Metastatic castration-resistant prostate cancer (mCRPC) is immunologically "cold" and predominantly resistant to immune checkpoint therapy due to few tumor-infiltrating T cells. Ipilimumab (anti-CTLA-4) or anti-PD-1/PD-L1 monotherapy failed t
Autor:
B. Sharkey, W.R. Clark, Marika Ciprotti, Karim Fizazi, Charles G. Drake, Fred Saad, S.K. Subudhi
Publikováno v:
Annals of Oncology. 31:S546
Autor:
Daniel P. Petrylak, Fred Saad, Russell K. Pachynski, Charles G. Drake, David R. Shaffer, J.N. Minatta, Xuya Wang, Abdel Saci, B. Sharkey, Marika Ciprotti, Andrew J. Armstrong, H.M. Sanchez Lopez, J.C. Vazquez Limon, Daniel Castellano, Margitta Retz, Jia Li, Karim Fizazi, P. Gonzalez Mella, A. Rezazadeh Kalebasty, P. Sathyanarayana
Publikováno v:
Annals of Oncology. 30:v885-v886
Background The antitumor activity of programmed death-1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibition alone is limited in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Combining immunotherapy with standard-of-care chemotherap
Autor:
Rira Watanabe, Archie N. Tse, David C. McKee, Mendel Jansen, Sze Ting Lee, Graeme O'Keefe, Martin W. Brechbiel, Fook-Thean Lee, Niall C. Tebbutt, Geoffrey Chong, Andrew M. Scott, Marika Ciprotti, Wendie Hopkins, Manabu Matsumura, Jonathan Greenberg, Fiona Scott, Masakatsu Kotsuma, Sylvia J. Gong, Ralph Venhaus, Bridget Chappell, Robert A. Beckman, Hui K Gan
Publikováno v:
Journal of Clinical Oncology. 33:2609-2616
Purpose CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake,
Publikováno v:
Nuclear Oncology ISBN: 9783319260679
Nuclear Oncology
Nuclear Oncology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e1095377f13ed8044f80921c4d9936
https://doi.org/10.1007/978-3-319-26236-9_24
https://doi.org/10.1007/978-3-319-26236-9_24
Autor:
Hakim Mahammedi, Sarah Hu, Vivek Narayan, Abdel Saci, G. Celine Han, Matthew D. Galsky, Gwenaelle Gravis, Akash Patnaik, Marika Ciprotti, Russell K. Pachynski, Tao Duan, Aude Flechon, Sumit K. Subudhi, Karim Fizazi, Padmanee Sharma
Publikováno v:
Journal of Clinical Oncology. 37:142-142
142 Background: Immune checkpoint inhibitor monotherapy has shown limited clinical benefit in patients (pts) with prostate cancer, likely due to an immunologically “cold” tumor microenvironment. We report preplanned interim efficacy/safety for NI